NCT07160335View on ClinicalTrials.gov

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

March 27, 2028

Conditions
Non-small Cell Lung CancerMelanomaRenal Cell Carcinoma
Interventions
DRUG

HLX17

Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle

DRUG

US-sourced Keytruda®

Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY